Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 123

1.

Targeting sickle cell disease root-cause pathophysiology with small molecules.

Saunthararajah Y.

Haematologica. 2019 Sep;104(9):1720-1730. doi: 10.3324/haematol.2018.207530. Epub 2019 Aug 8. Review.

2.

Cytokine-Regulated Phosphorylation and Activation of TET2 by JAK2 in Hematopoiesis.

Jeong JJ, Gu X, Nie J, Sundaravel S, Liu H, Kuo WL, Bhagat TD, Pradhan K, Cao J, Nischal S, McGraw KL, Bhattacharyya S, Bishop MR, Artz A, Thirman MJ, Moliterno A, Ji P, Levine RL, Godley LA, Steidl U, Bieker JJ, List AF, Saunthararajah Y, He C, Verma A, Wickrema A.

Cancer Discov. 2019 Jun;9(6):778-795. doi: 10.1158/2159-8290.CD-18-1138. Epub 2019 Apr 3.

PMID:
30944118
3.

EZH2 Inhibitors: Take It EZy, It Is All About Context.

Velcheti V, Wong KK, Saunthararajah Y.

Cancer Discov. 2019 Apr;9(4):472-475. doi: 10.1158/2159-8290.CD-19-0090.

PMID:
30936220
4.

Tracking Decitabine Incorporation into Malignant Myeloid Cell DNA in vitro and in vivo by LC-MS/MS with Enzymatic Digestion.

Chilakala S, Feng Y, Li L, Mahfouz R, Quteba E, Saunthararajah Y, Xu Y.

Sci Rep. 2019 Mar 14;9(1):4558. doi: 10.1038/s41598-019-41070-y.

5.

OAS-RNase L innate immune pathway mediates the cytotoxicity of a DNA-demethylating drug.

Banerjee S, Gusho E, Gaughan C, Dong B, Gu X, Holvey-Bates E, Talukdar M, Li Y, Weiss SR, Sicheri F, Saunthararajah Y, Stark GR, Silverman RH.

Proc Natl Acad Sci U S A. 2019 Mar 12;116(11):5071-5076. doi: 10.1073/pnas.1815071116. Epub 2019 Feb 27.

6.

Using PU.1 and Jun dimerization protein 2 transcription factor expression in myelodysplastic syndromes to predict treatment response and leukaemia transformation.

Boasman K, Simmonds MJ, Graham C, Saunthararajah Y, Rinaldi CR.

Ann Hematol. 2019 Jun;98(6):1529-1531. doi: 10.1007/s00277-019-03627-9. Epub 2019 Feb 5. No abstract available.

PMID:
30721335
7.

CDC37 as a novel target for the treatment of NPM1-ALK expressing anaplastic large cell lymphomas.

Kuravi S, Parrott E, Mudduluru G, Cheng J, Ganguly S, Saunthararajah Y, Jensen RA, Blagg BS, McGuirk JP, Balusu R.

Blood Cancer J. 2019 Jan 29;9(2):14. doi: 10.1038/s41408-019-0171-2. No abstract available.

8.

Low-Dose Azacitidine with DNMT1 Level Monitoring to Treat Post-Transplantation Acute Myelogenous Leukemia or Myelodysplastic Syndrome Relapse.

Ueda M, El-Jurdi N, Cooper B, Caimi P, Baer L, Kolk M, Brister L, Wald DN, Otegbeye F, Lazarus HM, Sandmaier BM, William B, Saunthararajah Y, Woost P, Jacobberger JW, de Lima M.

Biol Blood Marrow Transplant. 2019 Jun;25(6):1122-1127. doi: 10.1016/j.bbmt.2018.12.764. Epub 2018 Dec 30.

PMID:
30599207
9.

Beta-Thalassemia Minor Manifesting as Proliferative Retinopathy.

Stultz RD, Conti FF, Kumar JB, Kotabish E, Schachat A, Ehlers JP, Saunthararajah Y, Singh RP.

Ophthalmic Surg Lasers Imaging Retina. 2018 Oct 1;49(10):e161-e164. doi: 10.3928/23258160-20181002-22.

PMID:
30395680
10.

Ultimate Precision: Targeting Cancer but Not Normal Self-replication.

Velcheti V, Schrump D, Saunthararajah Y.

Am Soc Clin Oncol Educ Book. 2018 May 23;38:950-963. doi: 10.1200/EDBK_199753. Review.

PMID:
30231326
11.

Differentiation therapy and the mechanisms that terminate cancer cell proliferation without harming normal cells.

Enane FO, Saunthararajah Y, Korc M.

Cell Death Dis. 2018 Sep 6;9(9):912. doi: 10.1038/s41419-018-0919-9. Review.

12.

Oral administration of the LSD1 inhibitor ORY-3001 increases fetal hemoglobin in sickle cell mice and baboons.

Rivers A, Vaitkus K, Jagadeeswaran R, Ruiz MA, Ibanez V, Ciceri F, Cavalcanti F, Molokie RE, Saunthararajah Y, Engel JD, DeSimone J, Lavelle D.

Exp Hematol. 2018 Nov;67:60-64.e2. doi: 10.1016/j.exphem.2018.08.003. Epub 2018 Aug 17.

PMID:
30125603
13.

Leukemogenic nucleophosmin mutation disrupts the transcription factor hub that regulates granulomonocytic fates.

Gu X, Ebrahem Q, Mahfouz RZ, Hasipek M, Enane F, Radivoyevitch T, Rapin N, Przychodzen B, Hu Z, Balusu R, Cotta CV, Wald D, Argueta C, Landesman Y, Martelli MP, Falini B, Carraway H, Porse BT, Maciejewski J, Jha BK, Saunthararajah Y.

J Clin Invest. 2018 Oct 1;128(10):4260-4279. doi: 10.1172/JCI97117. Epub 2018 Jul 17.

14.

Fetal Hemoglobin Induction by Epigenetic Drugs.

Lavelle D, Engel JD, Saunthararajah Y.

Semin Hematol. 2018 Apr;55(2):60-67. doi: 10.1053/j.seminhematol.2018.04.008. Epub 2018 Apr 22. Review.

15.

A Novel l-Asparaginase with low l-Glutaminase Coactivity Is Highly Efficacious against Both T- and B-cell Acute Lymphoblastic Leukemias In Vivo.

Nguyen HA, Su Y, Zhang JY, Antanasijevic A, Caffrey M, Schalk AM, Liu L, Rondelli D, Oh A, Mahmud DL, Bosland MC, Kajdacsy-Balla A, Peirs S, Lammens T, Mondelaers V, De Moerloose B, Goossens S, Schlicht MJ, Kabirov KK, Lyubimov AV, Merrill BJ, Saunthararajah Y, Van Vlierberghe P, Lavie A.

Cancer Res. 2018 Mar 15;78(6):1549-1560. doi: 10.1158/0008-5472.CAN-17-2106. Epub 2018 Jan 17.

16.

Severe pyoderma gangrenosum caused by myelodysplastic syndrome successfully treated with decitabine administered by a noncytotoxic regimen.

Saleh MFM, Saunthararajah Y.

Clin Case Rep. 2017 Oct 31;5(12):2025-2027. doi: 10.1002/ccr3.1221. eCollection 2017 Dec.

17.

Oral tetrahydrouridine and decitabine for non-cytotoxic epigenetic gene regulation in sickle cell disease: A randomized phase 1 study.

Molokie R, Lavelle D, Gowhari M, Pacini M, Krauz L, Hassan J, Ibanez V, Ruiz MA, Ng KP, Woost P, Radivoyevitch T, Pacelli D, Fada S, Rump M, Hsieh M, Tisdale JF, Jacobberger J, Phelps M, Engel JD, Saraf S, Hsu LL, Gordeuk V, DeSimone J, Saunthararajah Y.

PLoS Med. 2017 Sep 7;14(9):e1002382. doi: 10.1371/journal.pmed.1002382. eCollection 2017 Sep.

18.

GATA4 loss of function in liver cancer impedes precursor to hepatocyte transition.

Enane FO, Shuen WH, Gu X, Quteba E, Przychodzen B, Makishima H, Bodo J, Ng J, Chee CL, Ba R, Seng Koh L, Lim J, Cheong R, Teo M, Hu Z, Ng KP, Maciejewski J, Radivoyevitch T, Chung A, Ooi LL, Tan YM, Cheow PC, Chow P, Chan CY, Lim KH, Yerian L, Hsi E, Toh HC, Saunthararajah Y.

J Clin Invest. 2017 Sep 1;127(9):3527-3542. doi: 10.1172/JCI93488. Epub 2017 Jul 31.

19.
20.

Higher-Level Pathway Objectives of Epigenetic Therapy: A Solution to the p53 Problem in Cancer.

Velcheti V, Radivoyevitch T, Saunthararajah Y.

Am Soc Clin Oncol Educ Book. 2017;37:812-824. doi: 10.14694/EDBK_174175. Review.

PMID:
28561650
21.

Recurrent genetic defects on chromosome 5q in myeloid neoplasms.

Hosono N, Makishima H, Mahfouz R, Przychodzen B, Yoshida K, Jerez A, LaFramboise T, Polprasert C, Clemente MJ, Shiraishi Y, Chiba K, Tanaka H, Miyano S, Sanada M, Cui E, Verma AK, McDevitt MA, List AF, Saunthararajah Y, Sekeres MA, Boultwood J, Ogawa S, Maciejewski JP.

Oncotarget. 2017 Jan 24;8(4):6483-6495. doi: 10.18632/oncotarget.14130.

22.

Dynamics of clonal evolution in myelodysplastic syndromes.

Makishima H, Yoshizato T, Yoshida K, Sekeres MA, Radivoyevitch T, Suzuki H, Przychodzen B, Nagata Y, Meggendorfer M, Sanada M, Okuno Y, Hirsch C, Kuzmanovic T, Sato Y, Sato-Otsubo A, LaFramboise T, Hosono N, Shiraishi Y, Chiba K, Haferlach C, Kern W, Tanaka H, Shiozawa Y, Gómez-Seguí I, Husseinzadeh HD, Thota S, Guinta KM, Dienes B, Nakamaki T, Miyawaki S, Saunthararajah Y, Chiba S, Miyano S, Shih LY, Haferlach T, Ogawa S, Maciejewski JP.

Nat Genet. 2017 Feb;49(2):204-212. doi: 10.1038/ng.3742. Epub 2016 Dec 19.

PMID:
27992414
23.

Association of tumor and plasma microRNA expression with tumor monosomy-3 in patients with uveal melanoma.

Triozzi PL, Achberger S, Aldrich W, Crabb JW, Saunthararajah Y, Singh AD.

Clin Epigenetics. 2016 Jul 22;8:80. doi: 10.1186/s13148-016-0243-0. eCollection 2016.

24.

GSK-3 Inhibition Sensitizes Acute Myeloid Leukemia Cells to 1,25D-Mediated Differentiation.

Gupta K, Stefan T, Ignatz-Hoover J, Moreton S, Parizher G, Saunthararajah Y, Wald DN.

Cancer Res. 2016 May 1;76(9):2743-53. doi: 10.1158/0008-5472.CAN-15-2290. Epub 2016 Mar 10.

25.

Identification of a Small Molecule That Overcomes HdmX-Mediated Suppression of p53.

Karan G, Wang H, Chakrabarti A, Karan S, Liu Z, Xia Z, Gundluru M, Moreton S, Saunthararajah Y, Jackson MW, Agarwal MK, Wald DN.

Mol Cancer Ther. 2016 Apr;15(4):574-582. doi: 10.1158/1535-7163.MCT-15-0467. Epub 2016 Feb 16.

26.

The LSD1 inhibitor RN-1 recapitulates the fetal pattern of hemoglobin synthesis in baboons (P. anubis).

Rivers A, Vaitkus K, Ibanez V, Ruiz MA, Jagadeeswaran R, Saunthararajah Y, Cui S, Engel JD, DeSimone J, Lavelle D.

Haematologica. 2016 Jun;101(6):688-97. doi: 10.3324/haematol.2015.140749. Epub 2016 Feb 8.

27.

Correction: Methylation Profiles Reveal Distinct Subgroup of Hepatocellular Carcinoma Patients with Poor Prognosis.

Mah WC, Thurnherr T, Chow PK, Chung AY, Ooi LL, Toh HC, Teh BT, Saunthararajah Y, Lee CG.

PLoS One. 2016 Jan 11;11(1):e0146690. doi: 10.1371/journal.pone.0146690. eCollection 2016. No abstract available.

28.

Prospective Clinical Study of Precision Oncology in Solid Tumors.

Sohal DP, Rini BI, Khorana AA, Dreicer R, Abraham J, Procop GW, Saunthararajah Y, Pennell NA, Stevenson JP, Pelley R, Estfan B, Shepard D, Funchain P, Elson P, Adelstein DJ, Bolwell BJ.

J Natl Cancer Inst. 2015 Nov 9;108(3). pii: djv332. doi: 10.1093/jnci/djv332.

PMID:
26553780
29.

Cx25 contributes to leukemia cell communication and chemosensitivity.

Sinyuk M, Alvarado AG, Nesmiyanov P, Shaw J, Mulkearns-Hubert EE, Eurich JT, Hale JS, Bogdanova A, Hitomi M, Maciejewski J, Huang AY, Saunthararajah Y, Lathia JD.

Oncotarget. 2015 Oct 13;6(31):31508-21. doi: 10.18632/oncotarget.5226.

30.

iTRAQ Quantitative Proteomic Comparison of Metastatic and Non-Metastatic Uveal Melanoma Tumors.

Crabb JW, Hu B, Crabb JS, Triozzi P, Saunthararajah Y, Tubbs R, Singh AD.

PLoS One. 2015 Aug 25;10(8):e0135543. doi: 10.1371/journal.pone.0135543. eCollection 2015.

31.

The LSD1 inhibitor RN-1 induces fetal hemoglobin synthesis and reduces disease pathology in sickle cell mice.

Cui S, Lim KC, Shi L, Lee M, Jearawiriyapaisarn N, Myers G, Campbell A, Harro D, Iwase S, Trievel RC, Rivers A, DeSimone J, Lavelle D, Saunthararajah Y, Engel JD.

Blood. 2015 Jul 16;126(3):386-96. doi: 10.1182/blood-2015-02-626259. Epub 2015 Jun 1.

32.

Targets of opportunity for precision medicine.

Saunthararajah Y.

Blood. 2015 May 14;125(20):3041-2. doi: 10.1182/blood-2015-04-638270. No abstract available.

33.

Inherited and Somatic Defects in DDX41 in Myeloid Neoplasms.

Polprasert C, Schulze I, Sekeres MA, Makishima H, Przychodzen B, Hosono N, Singh J, Padgett RA, Gu X, Phillips JG, Clemente M, Parker Y, Lindner D, Dienes B, Jankowsky E, Saunthararajah Y, Du Y, Oakley K, Nguyen N, Mukherjee S, Pabst C, Godley LA, Churpek JE, Pollyea DA, Krug U, Berdel WE, Klein HU, Dugas M, Shiraishi Y, Chiba K, Tanaka H, Miyano S, Yoshida K, Ogawa S, Müller-Tidow C, Maciejewski JP.

Cancer Cell. 2015 May 11;27(5):658-70. doi: 10.1016/j.ccell.2015.03.017. Epub 2015 Apr 23.

34.

Evaluation of noncytotoxic DNMT1-depleting therapy in patients with myelodysplastic syndromes.

Saunthararajah Y, Sekeres M, Advani A, Mahfouz R, Durkin L, Radivoyevitch T, Englehaupt R, Juersivich J, Cooper K, Husseinzadeh H, Przychodzen B, Rump M, Hobson S, Earl M, Sobecks R, Dean R, Reu F, Tiu R, Hamilton B, Copelan E, Lichtin A, Hsi E, Kalaycio M, Maciejewski J.

J Clin Invest. 2015 Mar 2;125(3):1043-55. doi: 10.1172/JCI78789. Epub 2015 Jan 26.

35.

Impact of vancomycin-resistant enterococcal bacteremia on outcome during acute myeloid leukemia induction therapy.

Ornstein MC, Mukherjee S, Keng M, Elson P, Tiu RV, Saunthararajah Y, Maggiotto A, Schaub M, Banks D, Advani A, Kalaycio M, Maciejewski JP, Sekeres MA.

Leuk Lymphoma. 2015;56(9):2536-42. doi: 10.3109/10428194.2014.1003557. Epub 2015 Feb 20.

PMID:
25563427
36.

Splicing factor 3b subunit 1 (Sf3b1) haploinsufficient mice display features of low risk Myelodysplastic syndromes with ring sideroblasts.

Visconte V, Tabarroki A, Zhang L, Parker Y, Hasrouni E, Mahfouz R, Isono K, Koseki H, Sekeres MA, Saunthararajah Y, Barnard J, Lindner D, Rogers HJ, Tiu RV.

J Hematol Oncol. 2014 Dec 7;7:89. doi: 10.1186/s13045-014-0089-x.

37.

Genomic microarray analysis on formalin-fixed paraffin-embedded material for uveal melanoma prognostication.

Minca EC, Tubbs RR, Portier BP, Wang Z, Lanigan C, Aronow ME, Triozzi PL, Singh A, Cook JR, Saunthararajah Y, Plesec TP, Schoenfield L, Cawich V, Sulpizio S, Schultz RA.

Cancer Genet. 2014 Jul-Aug;207(7-8):306-15. doi: 10.1016/j.cancergen.2014.08.005. Epub 2014 Aug 29.

PMID:
25442074
38.

Methylation profiles reveal distinct subgroup of hepatocellular carcinoma patients with poor prognosis.

Mah WC, Thurnherr T, Chow PK, Chung AY, Ooi LL, Toh HC, Teh BT, Saunthararajah Y, Lee CG.

PLoS One. 2014 Aug 5;9(8):e104158. doi: 10.1371/journal.pone.0104158. eCollection 2014. Erratum in: PLoS One. 2016;11(1):e0146690.

39.

Decitabine suspends human CD34+ cell differentiation and proliferation during lentiviral transduction.

Uchida N, Hsieh MM, Platner C, Saunthararajah Y, Tisdale JF.

PLoS One. 2014 Aug 4;9(8):e104022. doi: 10.1371/journal.pone.0104022. eCollection 2014.

40.

Ligand exchange on gold nanoparticles for drug delivery and enhanced therapeutic index evaluated in acute myeloid leukemia models.

Egusa S, Ebrahem Q, Mahfouz RZ, Saunthararajah Y.

Exp Biol Med (Maywood). 2014 Jul;239(7):853-861. Epub 2014 May 30.

PMID:
24879424
41.

Distinct iron architecture in SF3B1-mutant myelodysplastic syndrome patients is linked to an SLC25A37 splice variant with a retained intron.

Visconte V, Avishai N, Mahfouz R, Tabarroki A, Cowen J, Sharghi-Moshtaghin R, Hitomi M, Rogers HJ, Hasrouni E, Phillips J, Sekeres MA, Heuer AH, Saunthararajah Y, Barnard J, Tiu RV.

Leukemia. 2015 Jan;29(1):188-95. doi: 10.1038/leu.2014.170. Epub 2014 May 23.

PMID:
24854990
42.

Clinicopathologic and molecular characterization of myeloid neoplasms harboring isochromosome 17(q10).

Visconte V, Tabarroki A, Zhang L, Hasrouni E, Gerace C, Frum R, Ai J, Advani AS, Duong HK, Kalaycio M, Saunthararajah Y, Sekeres MA, His ED, Shetty S, Rogers HJ, Tiu RV.

Am J Hematol. 2014 Aug;89(8):862. doi: 10.1002/ajh.23755. Epub 2014 May 16. No abstract available.

43.

Ruxolitinib in combination with DNA methyltransferase inhibitors: clinical responses in patients with symptomatic myelofibrosis with cytopenias and elevated blast(s) counts.

Tabarroki A, Saunthararajah Y, Visconte V, Cinalli T, Colaluca K, Rogers HJ, Sekeres MA, Duong HK, Stein BL, Tiu RV.

Leuk Lymphoma. 2015 Feb;56(2):497-9. doi: 10.3109/10428194.2014.916805. Epub 2014 May 27. No abstract available.

PMID:
24766471
44.

Runx1 regulation of Pu.1 corepressor/coactivator exchange identifies specific molecular targets for leukemia differentiation therapy.

Gu X, Hu Z, Ebrahem Q, Crabb JS, Mahfouz RZ, Radivoyevitch T, Crabb JW, Saunthararajah Y.

J Biol Chem. 2014 May 23;289(21):14881-95. doi: 10.1074/jbc.M114.562447. Epub 2014 Apr 2.

45.

Subchronic oral toxicity study of decitabine in combination with tetrahydrouridine in CD-1 mice.

Terse P, Engelke K, Chan K, Ling Y, Sharpnack D, Saunthararajah Y, Covey JM.

Int J Toxicol. 2014 Mar-Apr;33(2):75-85. doi: 10.1177/1091581814524994. Epub 2014 Mar 17.

46.

Risk for developing myelodysplastic syndromes in prostate cancer patients definitively treated with radiation.

Mukherjee S, Reddy CA, Ciezki JP, Abdel-Wahab M, Tiu RV, Copelan E, Advani AA, Saunthararajah Y, Paulic K, Hobson S, Maciejewski JP, Bolwell BJ, Kalaycio M, Dreicer R, Klein EA, Sekeres MA.

J Natl Cancer Inst. 2014 Mar;106(3):djt462. doi: 10.1093/jnci/djt462. Epub 2014 Feb 27.

PMID:
24577815
47.

Sex differences in the incidence of chronic myeloid leukemia.

Radivoyevitch T, Jankovic GM, Tiu RV, Saunthararajah Y, Jackson RC, Hlatky LR, Gale RP, Sachs RK.

Radiat Environ Biophys. 2014 Mar;53(1):55-63. doi: 10.1007/s00411-013-0507-4. Epub 2013 Dec 13.

48.

Ribosomal S6 kinase and AKT phosphorylation as pharmacodynamic biomarkers in patients with myelodysplastic syndrome treated with RAD001.

Advani AS, Mahfouz RZ, Maciejewski J, Rybicki L, Sekeres M, Tripp B, Kalaycio M, Bates J, Saunthararajah Y.

Clin Lymphoma Myeloma Leuk. 2014 Apr;14(2):172-177.e1. doi: 10.1016/j.clml.2013.10.001. Epub 2013 Nov 11.

PMID:
24332215
49.

Key clinical observations after 5-azacytidine and decitabine treatment of myelodysplastic syndromes suggest practical solutions for better outcomes.

Saunthararajah Y.

Hematology Am Soc Hematol Educ Program. 2013;2013:511-21. doi: 10.1182/asheducation-2013.1.511. Review.

PMID:
24319226
50.

Sex difference in myelodysplastic syndrome survival and balance in randomized clinical trials.

Radivoyevitch T, Saunthararajah Y.

J Clin Oncol. 2014 Jan 1;32(1):60-1. doi: 10.1200/JCO.2013.52.5980. Epub 2013 Nov 18. No abstract available.

PMID:
24248691

Supplemental Content

Loading ...
Support Center